# Trastuzumab Emtansine

## Kadcyla inj 100mg \(sample\)

| 藥物代碼 | IKAD0 |
| :--- | :--- |
| 適應症 | Metastatic breast cancer, HER2 overexpression, monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy. |
| 副作用 | Common■Gastrointestinal: Constipation \(26.5% \), Nausea \(39.8% \)■Hematologic: Thrombocytopenia, All grades \(31.2% \)■Hepatic: Increased liver enzymes, All grades \(28.8% \)■Musculoskeletal: Musculoskeletal pain \(36.1% \)■Neurologic: Headache \(28.2% \)■Other: Fatigue \(36.3% \)Serious■Cardiovascular: Left ventricular cardiac dysfunction \(1.8% \)■Dermatologic: Injection site extravasation■Hematologic: Anemia, Grade 3 and 4 \(4.1% \), Neutropenia, Grade 3 and 4 \(2% \), Thrombocytopenia, Grade 3 and 4 \(14.5% \)■Hepatic: Hepatotoxicity, Increased liver enzymes, Grades 3 and 4 \(8% \), Injury of liver■Immunologic: Anaphylactoid reaction■Neurologic: Peripheral nerve disease, Grade 3 or 4 \(2.2% \)■Respiratory: Dyspnea \(12% \), Interstitial lung disease, Pneumonitis \(0.8% to 1.2% \) |
| 禁忌 | Specific contraindications have not been determined. |
| 藥物保存方式 | 2-8℃ |
| 用法用量 | \*Do NOT substitute trastuzumab emtansine \(Kadcyla\(TM\)\) for trastuzumab \(Herceptin\(R\)\) Metastatic breast cancer, HER2 overexpression, monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy: trastuzumab emtansine \(Kadcyla\(TM\)\), 3.6 mg/kg IV infusion every 3 weeks \(21-day cycle\); infuse first infusion over 90 minutes and subsequent infusions over 30 minutes; do not exceed 3.6 mg/kg dose; if a dose must be delayed or missed, administer as soon as possible without waiting until the next planned cycle; adjust to maintain a 3-week interval between doses. |
| 肝功能異常 | 無需調整劑量  Mild to moderate impairment \(Child-Pugh class A or B\): No dosage adjustment necessary; use with caution. Severe impairment \(Child-Pugh class C\): There are no dosage adjustments provided in the manufacturer's labeling \(has not been studied\). |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | Lactation studies with trastuzumab emtansine have not been conducted. Small amounts of trastuzumab were excreted in the milk of lactating monkeys following postpartum administration of trastuzumab in doses up to 25 mg/kg \(approximately 7 times the recommended human dose\). It is unknown whether ado-trastuzumab emtansine is excreted into human milk. Because many drugs are excreted in human milk and risk to the nursing infant cannot be excluded, a decision should be made to discontinue treatment or discontinue nursing taking into account the importance of the drug to the mother. |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 輸注溶液不可含葡萄糖。 2. 第一次使用建議施打90分鐘，之後視病人耐受程度可縮短輸注時間至最短30 分鐘。請使用0.2-0.22微米、不吸附蛋白質的管線內 polyethersulfone \(PES\)過濾器。 3. 溶液配置後應立即使用，冷藏於2-8℃最多儲存24小時。 4. 輸注時注意病人是否出現呼吸困難、周邊水腫、低血壓或其他急性過敏反應症狀。 5. 監測CBC、肝腎功能。 |

## KADCYLA inj 160mg \(sample\)

| 藥物代碼 | IKAD00 |
| :--- | :--- |
| 適應症 | Metastatic breast cancer, HER2 overexpression, monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy. |
| 副作用 | Common■Gastrointestinal: Constipation \(26.5% \), Nausea \(39.8% \)■Hematologic: Thrombocytopenia, All grades \(31.2% \)■Hepatic: Increased liver enzymes, All grades \(28.8% \)■Musculoskeletal: Musculoskeletal pain \(36.1% \)■Neurologic: Headache \(28.2% \)■Other: Fatigue \(36.3% \)Serious■Cardiovascular: Left ventricular cardiac dysfunction \(1.8% \)■Dermatologic: Injection site extravasation■Hematologic: Anemia, Grade 3 and 4 \(4.1% \), Neutropenia, Grade 3 and 4 \(2% \), Thrombocytopenia, Grade 3 and 4 \(14.5% \)■Hepatic: Hepatotoxicity, Increased liver enzymes, Grades 3 and 4 \(8% \), Injury of liver■Immunologic: Anaphylactoid reaction■Neurologic: Peripheral nerve disease, Grade 3 or 4 \(2.2% \)■Respiratory: Dyspnea \(12% \), Interstitial lung disease, Pneumonitis \(0.8% to 1.2% \) |
| 禁忌 | Specific contraindications have not been determined. |
| 藥物保存方式 | 2-8℃ |
| 用法用量 | \*Do NOT substitute trastuzumab emtansine \(Kadcyla\(TM\)\) for trastuzumab \(Herceptin\(R\)\) Metastatic breast cancer, HER2 overexpression, monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy: trastuzumab emtansine \(Kadcyla\(TM\)\), 3.6 mg/kg IV infusion every 3 weeks \(21-day cycle\); infuse first infusion over 90 minutes and subsequent infusions over 30 minutes; do not exceed 3.6 mg/kg dose; if a dose must be delayed or missed, administer as soon as possible without waiting until the next planned cycle; adjust to maintain a 3-week interval between doses. |
| 肝功能異常 | 無需調整劑量  Mild to moderate impairment \(Child-Pugh class A or B\): No dosage adjustment necessary; use with caution. Severe impairment \(Child-Pugh class C\): There are no dosage adjustments provided in the manufacturer's labeling \(has not been studied\). |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | Lactation studies with trastuzumab emtansine have not been conducted. Small amounts of trastuzumab were excreted in the milk of lactating monkeys following postpartum administration of trastuzumab in doses up to 25 mg/kg \(approximately 7 times the recommended human dose\). It is unknown whether ado-trastuzumab emtansine is excreted into human milk. Because many drugs are excreted in human milk and risk to the nursing infant cannot be excluded, a decision should be made to discontinue treatment or discontinue nursing taking into account the importance of the drug to the mother. |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 輸注溶液不可含葡萄糖。 2. 第一次使用建議施打90分鐘，之後視病人耐受程度可縮短輸注時間至最短30 分鐘。請使用0.2-0.22微米、不吸附蛋白質的管線內 polyethersulfone \(PES\)過濾器。 3. 溶液配置後應立即使用，冷藏於2-8℃最多儲存24小時。 4. 輸注時注意病人是否出現呼吸困難、周邊水腫、低血壓或其他急性過敏反應症狀。 5. 監測CBC、肝腎功能。 |

## Kadcyla inj 100mg

| 藥物代碼 | IKAD1 |
| :--- | :--- |
| 適應症 | Metastatic breast cancer, HER2 overexpression, monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy. |
| 副作用 | Common■Gastrointestinal: Constipation \(26.5% \), Nausea \(39.8% \)■Hematologic: Thrombocytopenia, All grades \(31.2% \)■Hepatic: Increased liver enzymes, All grades \(28.8% \)■Musculoskeletal: Musculoskeletal pain \(36.1% \)■Neurologic: Headache \(28.2% \)■Other: Fatigue \(36.3% \)Serious■Cardiovascular: Left ventricular cardiac dysfunction \(1.8% \)■Dermatologic: Injection site extravasation■Hematologic: Anemia, Grade 3 and 4 \(4.1% \), Neutropenia, Grade 3 and 4 \(2% \), Thrombocytopenia, Grade 3 and 4 \(14.5% \)■Hepatic: Hepatotoxicity, Increased liver enzymes, Grades 3 and 4 \(8% \), Injury of liver■Immunologic: Anaphylactoid reaction■Neurologic: Peripheral nerve disease, Grade 3 or 4 \(2.2% \)■Respiratory: Dyspnea \(12% \), Interstitial lung disease, Pneumonitis \(0.8% to 1.2% \) |
| 禁忌 | Specific contraindications have not been determined. |
| 藥物保存方式 | 2-8℃ |
| 用法用量 | \*Do NOT substitute trastuzumab emtansine \(Kadcyla\(TM\)\) for trastuzumab \(Herceptin\(R\)\) Metastatic breast cancer, HER2 overexpression, monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy: trastuzumab emtansine \(Kadcyla\(TM\)\), 3.6 mg/kg IV infusion every 3 weeks \(21-day cycle\); infuse first infusion over 90 minutes and subsequent infusions over 30 minutes; do not exceed 3.6 mg/kg dose; if a dose must be delayed or missed, administer as soon as possible without waiting until the next planned cycle; adjust to maintain a 3-week interval between doses. |
| 肝功能異常 | 無需調整劑量  Mild to moderate impairment \(Child-Pugh class A or B\): No dosage adjustment necessary; use with caution. Severe impairment \(Child-Pugh class C\): There are no dosage adjustments provided in the manufacturer's labeling \(has not been studied\). |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | Lactation studies with trastuzumab emtansine have not been conducted. Small amounts of trastuzumab were excreted in the milk of lactating monkeys following postpartum administration of trastuzumab in doses up to 25 mg/kg \(approximately 7 times the recommended human dose\). It is unknown whether ado-trastuzumab emtansine is excreted into human milk. Because many drugs are excreted in human milk and risk to the nursing infant cannot be excluded, a decision should be made to discontinue treatment or discontinue nursing taking into account the importance of the drug to the mother. |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 輸注溶液不可含葡萄糖。 2. 第一次使用建議施打90分鐘，之後視病人耐受程度可縮短輸注時間至最短30 分鐘。請使用0.2-0.22微米、不吸附蛋白質的管線內 polyethersulfone \(PES\)過濾器。 3. 溶液配置後應立即使用，冷藏於2-8℃最多儲存24小時。 4. 輸注時注意病人是否出現呼吸困難、周邊水腫、低血壓或其他急性過敏反應症狀。 5. 監測CBC、肝腎功能。 |

## KADCYLA inj 160mg

| 藥物代碼 | IKAD6 |
| :--- | :--- |
| 適應症 | Metastatic breast cancer, HER2 overexpression, monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy. |
| 副作用 | Common■Gastrointestinal: Constipation \(26.5% \), Nausea \(39.8% \)■Hematologic: Thrombocytopenia, All grades \(31.2% \)■Hepatic: Increased liver enzymes, All grades \(28.8% \)■Musculoskeletal: Musculoskeletal pain \(36.1% \)■Neurologic: Headache \(28.2% \)■Other: Fatigue \(36.3% \)Serious■Cardiovascular: Left ventricular cardiac dysfunction \(1.8% \)■Dermatologic: Injection site extravasation■Hematologic: Anemia, Grade 3 and 4 \(4.1% \), Neutropenia, Grade 3 and 4 \(2% \), Thrombocytopenia, Grade 3 and 4 \(14.5% \)■Hepatic: Hepatotoxicity, Increased liver enzymes, Grades 3 and 4 \(8% \), Injury of liver■Immunologic: Anaphylactoid reaction■Neurologic: Peripheral nerve disease, Grade 3 or 4 \(2.2% \)■Respiratory: Dyspnea \(12% \), Interstitial lung disease, Pneumonitis \(0.8% to 1.2% \) |
| 禁忌 | Specific contraindications have not been determined. |
| 藥物保存方式 | 2-8℃ |
| 用法用量 | \*Do NOT substitute trastuzumab emtansine \(Kadcyla\(TM\)\) for trastuzumab \(Herceptin\(R\)\) Metastatic breast cancer, HER2 overexpression, monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy: trastuzumab emtansine \(Kadcyla\(TM\)\), 3.6 mg/kg IV infusion every 3 weeks \(21-day cycle\); infuse first infusion over 90 minutes and subsequent infusions over 30 minutes; do not exceed 3.6 mg/kg dose; if a dose must be delayed or missed, administer as soon as possible without waiting until the next planned cycle; adjust to maintain a 3-week interval between doses. |
| 肝功能異常 | 無需調整劑量  Mild to moderate impairment \(Child-Pugh class A or B\): No dosage adjustment necessary; use with caution. Severe impairment \(Child-Pugh class C\): There are no dosage adjustments provided in the manufacturer's labeling \(has not been studied\). |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | Lactation studies with trastuzumab emtansine have not been conducted. Small amounts of trastuzumab were excreted in the milk of lactating monkeys following postpartum administration of trastuzumab in doses up to 25 mg/kg \(approximately 7 times the recommended human dose\). It is unknown whether ado-trastuzumab emtansine is excreted into human milk. Because many drugs are excreted in human milk and risk to the nursing infant cannot be excluded, a decision should be made to discontinue treatment or discontinue nursing taking into account the importance of the drug to the mother. |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 輸注溶液不可含葡萄糖。 2. 第一次使用建議施打90分鐘，之後視病人耐受程度可縮短輸注時間至最短30 分鐘。請使用0.2-0.22微米、不吸附蛋白質的管線內 polyethersulfone \(PES\)過濾器。 3. 溶液配置後應立即使用，冷藏於2-8℃最多儲存24小時。 4. 輸注時注意病人是否出現呼吸困難、周邊水腫、低血壓或其他急性過敏反應症狀。 5. 監測CBC、肝腎功能。 |

